TYVASO DPI FDA approval date

The FDA approved TYVASO DPI on 23 May 2022.

FDA approval date
23 May 2022

Drug identity has not yet been verified against registry records

Also recorded as TREPROSTINIL

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-05-23DayTYVASO DPIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA214324", "applicant_as_listed_by_fda": "UNITED THERAP", "brand_names": ["TYVASO DPI"], "active_ingredients": ["TREPROSTINIL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220523", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026